B. Canard

The activation chain of the broad-spectrum antiviral bemnifosbuvir at atomic resolution

This paper reveals the activation pathway of bemnifosbuvir to its active form AT-9010, showing the required enzymes and structural insights into the process.

Fluoxetine targets an allosteric site in the enterovirus 2C AAA+ ATPase and stabilizes the hexameric complex

This study identifies fluoxetine as an inhibitor of the enterovirus 2C AAA+ ATPase, revealing its mechanism of action through structural and functional analyses.

Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir

The paper identifies simeprevir as a potent inhibitor of SARS-CoV-2 replication that synergizes with remdesivir in vitro.

A high-throughput fluorescence polarization assay to discover inhibitors of arenavirus and coronavirus exoribonucleases

This paper develops a high-throughput fluorescence polarization assay to screen inhibitors of exoribonucleases from arenaviruses and coronaviruses and validates it with a small compound library.

The nucleotide addition cycle of the SARS-CoV-2 polymerase

This study describes the mechanochemical behavior of the SARS-CoV-2 polymerase using magnetic tweezers, revealing three catalytic conformations and a thermal ratchet mechanism for nucleotide incorporation.

Protein-primed RNA synthesis in SARS-CoVs and structural basis for inhibition by AT-527

This paper identifies a protein-priming mechanism for SARS-CoV RNA synthesis and shows that AT-527 inhibits this process by targeting both NiRAN and RdRp domains.

A Fluorescence-based High Throughput-Screening assay for the SARS-CoV RNA synthesis complex

The paper describes a fluorescence-based high-throughput screening assay for identifying inhibitors of the SARS-CoV RNA synthesis complex using a purified and active replication/transcription complex.

AT-527 is a potent in vitro replication inhibitor of SARS-CoV-2, the virus responsible for the COVID-19 pandemic

The paper reports that AT-511, a form of AT-527, is a potent in vitro inhibitor of SARS-CoV-2 replication with low cytotoxicity.

Inhibition of SARS-CoV-2 polymerase by nucleotide analogs: a single moleculeperspective

This study investigates how nucleotide analogs like Remdesivir affect SARS-CoV-2 polymerase activity using single-molecule techniques, revealing backtracking rather than termination and evasion of ddhCTP.

Favipiravir strikes the SARS-CoV-2 at its Achilles heel, the RNA polymerase

This study shows Favipiravir inhibits SARS-CoV-2 by targeting its RNA polymerase through chain termination, slowed synthesis, and mutagenesis.

Arenaviridae exoribonuclease presents genomic RNA edition capacity.

This paper investigates the RNA exonuclease activity of Arenavirus ExoN, showing it edits genomic RNA and links to genome stability rather than innate immune suppression.